Valuation: Cipla Limited

Market Cap 1,178B 12.35B 10.7B 10.03B 9.15B 17.21B 17.49B 118B 46.12B 590B 46.36B 45.35B 1,968B P/E 2027 *
28.4x
P/E 2028 * 22.9x
Enterprise Value 1,072B 11.24B 9.74B 9.13B 8.33B 15.66B 15.92B 108B 41.97B 537B 42.19B 41.27B 1,791B EV / Sales 2027 *
3.46x
EV / Sales 2028 * 3.01x
Free-Float
68.87%
Yield 2027 *
0.89%
Yield 2028 * 1.01%
1 week-1.29%
Current month-0.65%
1 month+2.68%
3 months+10.07%
6 months+4.08%
Current year-8.93%
1 week 15.3
Extreme 15.3
15.3
1 month 14.4
Extreme 14.4
15.5
Current year 12.8
Extreme 12.8
17
1 year 12.8
Extreme 12.8
18.9
3 years 12.8
Extreme 12.8
20
5 years 10.4
Extreme 10.4
20
10 years 4.94
Extreme 4.94
20
Manager TitleAgeSince
Chief Executive Officer - 01/04/2026
President - 18/05/2026
Director of Finance/CFO - 24/07/2026
Director TitleAgeSince
Chairman 90 21/07/1972
Director/Board Member 72 25/07/2014
Director/Board Member 71 30/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.29% - - 12.35B
-0.10%-0.77%+17.58%+70.16% 48.57B
-3.26%-5.31%+53.19%+117.23% 40.99B
-0.60%-0.94%-7.29%+17.35% 12.35B
-2.75%+1.88%+14.81%+76.92% 12.2B
-0.19%-0.19%+29.10%+135.91% 9.08B
+0.70%+4.55%+22.32%+38.49% 7.41B
+0.52%+2.08%+40.75%-12.45% 7.13B
-0.07%+1.72%+13.39%+190.65% 6.86B
+1.45%+5.76%-25.73%+30.37% 5.92B
Average -0.43%+1.78%+17.57%+73.85% 16.72B
Weighted average by Cap. -1.01%+1.13%+25.15%+81.62%

Financials

2027 *2028 *
Net sales 310B 3.25B 2.81B 2.64B 2.41B 4.53B 4.6B 31.07B 12.13B 155B 12.19B 11.93B 517B 347B 3.64B 3.15B 2.96B 2.7B 5.07B 5.15B 34.82B 13.59B 174B 13.66B 13.37B 580B
Net income 41.35B 433M 376M 352M 321M 604M 614M 4.15B 1.62B 20.7B 1.63B 1.59B 69.05B 51.42B 539M 467M 438M 399M 751M 763M 5.15B 2.01B 25.74B 2.02B 1.98B 85.86B
Net Debt -106B -1.11B -963M -903M -823M -1.55B -1.57B -10.63B -4.15B -53.1B -4.17B -4.08B -177B -131B -1.38B -1.19B -1.12B -1.02B -1.92B -1.95B -13.18B -5.14B -65.8B -5.17B -5.06B -219B
Logo Cipla Limited
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Employees
31,369
Date Price Change
13/08/26 $15.30 0.00%
12/08/26 $15.30 0.00%
11/08/26 $15.30 0.00%
10/08/26 $15.30 -1.29%
07/08/26 $15.50 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
36
Last Close Price
1,458.80INR
Average target price
1,509.08INR
Spread / Average Target
+3.45%

Quarterly revenue - Rate of surprise